JAMA Network Home
Sign In
Research Letter

Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility

JAMA Oncology 10.1001/jamaoncol.2025.3869

October 09, 2025 at 11:00 AM EDT

Read the full article

This cross-sectional study examines absolute neutrophil count–related racial and ethnic disparities in cancer clinical trial eligibility using Duffy null status.

Corresponding Author: Andrew Hantel, MD, MPH, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115 (andrew_hantel@dfci.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.3869?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=100925

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks